Michael Goldberg, Surge Therapeutics founder and CEO
July 19, 2023 08:00 AM EDT
Financing

Im­munother­a­py dur­ing surgery? Surge Ther­a­peu­tics nabs $32M to ex­pand clin­i­cal plans af­ter first dos­ing

Amber Tong

Weeks ago, Surge Ther­a­peu­tics marked what CEO Michael Gold­berg hopes will go down in his­to­ry as a turn­ing point in can­cer care: the first time …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

Mer­ck KGaA clos­es in on Spring­Works deal at $3.5B price point

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times